Q-omics provides the consensus-scored GPR137C profile across patient tissues and cancer cell-line models. GPR137C expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GPR137C is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GPR137C RNA expression shows 19,931 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where GPR137C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR137C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR137C survival associations across molecular data types. GPR137C RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR137C RNA expression–survival associations across cancer types. High GPR137C expression shows unfavorable associations in ACC, UVM, MESO, KICH and LIHC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GPR137C RNA expression.
This table summarizes GPR137C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR137C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR137C shows higher tumor expression in HNSC, LIHC, UCEC, BRCA, BLCA and THCA. The HNSC box plot shows higher GPR137C RNA expression in tumor versus normal tissue (log2 FC = +0.310, t-test p < 0.001).
This table shows molecular features associated with GPR137C in patient tissues and cancer cell lines. In patient samples, GPR137C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR137C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
